CPC Main Group Additional Only
A61K 2239/00 Indexing codes associated with cellular immunotherapy of group A61K40/00
6 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- A61K 2239/10 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K 2239/27 characterized by targeting or presenting multiple antigens
- A61K 2239/31 characterized by the route of administration
- A61K 2239/38 characterised by the dose, timing or administration schedule
- A61K 2239/39 characterised by a specific adjuvant, e.g. cytokines or CpG
- A61K 2239/46 characterised by the cancer treated
Top Applicants
Top 10 applicants by patent filingsfor class A61, 2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 20,621
- NOVARTIS CH 15,792
- ROCHE CH 14,303
- COVIDIEN US 13,862
- HARVARD UNIVERSITY US 13,454
- UNIVERSITY OF CALIFORNIA US 12,798
- P&G (PROCTER & GAMBLE COMPANY) US 12,140
- L'OREAL FR 11,800
- OLYMPUS CORPORATION JP 9,894
- BOSTON SCIENTIFIC SCIMED US 9,513